Collagen VI myopathies: From the animal model to the clinical trial

Nadir M. Maraldi, Patrizia Sabatelli, Marta Columbaro, Alessandra Zamparelli, Francesco A. Manzoli, Paolo Bernardi, Paolo Bonaldo, Luciano Merlini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Collagen VI is an ECM protein which forms a prominent microfibrillar network in the endomysium of skeletal muscle. Mutations in the genes coding for the three chains of collagen VI cause skeletal muscle diseases; the severe wasting Ullrich congenital muscular dystrophy (UCMD) normally present at birth, and the milder Bethlem myopathy (BM). The pathogenesis of both collagen VI myopathies was unknown until 2003. Our group, utilizing Col6a1 deficient mice, discovered a latent mitochondrial dysfunction that caused increased apoptosis in muscle cells. These effects could be reverted by incubating Col6a1 null muscle fibres with cyclosporin A (CsA), an inhibitor of the mitochondrial permeability pore; more interestingly, the treatment of Col6a1 null mice with CoA rescued the muscle phenotype in vivo. These findings demonstrated an unexpected collagen VI/mitochondrial connection as the basis for the UCMD and BM pathogenesis and suggested a strategy for a possible pharmacological treatment of the diseases. This was assessed by demonstrating that muscle biopsies from patients with UCMD showed an abnormal mitochondrial depolarization and that treatment with CsA normalized the mitochondrial phenotype. In this study we report the results of an open pilot trial of four UCMD and one BM patients, representing a range of collagen VI deficiency and having mutations in three of the collagen VI genes. As determined in muscle biopsies prior to treatment, all patients displayed mitochondrial dysfunction and muscle fibres showed an increased frequency of apoptosis. When patients were treated for 1 month with a low daily dose of CsA, primary muscle cell cultures of biopsies obtained at the end of the treatment showed a decreased apoptosis and increased immunohistochemical signs of muscle fibre regeneration. These results confirm that the pathogenic mechanism found in Col6a1 deficient mice also plays a crucial role in hereditary muscle diseases in human, and suggest that targeted treatment of these mitochondrial defects in patients with UCMD and BM may be effective in preventing and/or reverting muscle alterations. It is also important to consider that desensitization of the permeability transition pore by CsA occurs independently of calcineurin inhibition; because a CsA derivative that has no immunosuppressive activity appears to be as effective as the parent molecule, long-term trials should be designed to prevent irreversible muscle damages in young patients affected by collagen VI myopathies, without exposing them to infective risks.

Original languageEnglish
Pages (from-to)197-211
Number of pages15
JournalAdvances in Enzyme Regulation
Volume49
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Muscular Diseases
Collagen
Animal Models
Clinical Trials
Muscles
Cyclosporine
Apoptosis
Biopsy
Muscle Cells
Permeability
Skeletal Muscle
Therapeutics
Phenotype
Mutation
Inborn Genetic Diseases
Primary Cell Culture
Calcineurin
Coenzyme A
Immunosuppressive Agents
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Collagen VI myopathies : From the animal model to the clinical trial. / Maraldi, Nadir M.; Sabatelli, Patrizia; Columbaro, Marta; Zamparelli, Alessandra; Manzoli, Francesco A.; Bernardi, Paolo; Bonaldo, Paolo; Merlini, Luciano.

In: Advances in Enzyme Regulation, Vol. 49, No. 1, 2009, p. 197-211.

Research output: Contribution to journalArticle

Maraldi, NM, Sabatelli, P, Columbaro, M, Zamparelli, A, Manzoli, FA, Bernardi, P, Bonaldo, P & Merlini, L 2009, 'Collagen VI myopathies: From the animal model to the clinical trial', Advances in Enzyme Regulation, vol. 49, no. 1, pp. 197-211. https://doi.org/10.1016/j.advenzreg.2008.12.009
Maraldi, Nadir M. ; Sabatelli, Patrizia ; Columbaro, Marta ; Zamparelli, Alessandra ; Manzoli, Francesco A. ; Bernardi, Paolo ; Bonaldo, Paolo ; Merlini, Luciano. / Collagen VI myopathies : From the animal model to the clinical trial. In: Advances in Enzyme Regulation. 2009 ; Vol. 49, No. 1. pp. 197-211.
@article{24efcb9bb2764063924c8d841887f772,
title = "Collagen VI myopathies: From the animal model to the clinical trial",
abstract = "Collagen VI is an ECM protein which forms a prominent microfibrillar network in the endomysium of skeletal muscle. Mutations in the genes coding for the three chains of collagen VI cause skeletal muscle diseases; the severe wasting Ullrich congenital muscular dystrophy (UCMD) normally present at birth, and the milder Bethlem myopathy (BM). The pathogenesis of both collagen VI myopathies was unknown until 2003. Our group, utilizing Col6a1 deficient mice, discovered a latent mitochondrial dysfunction that caused increased apoptosis in muscle cells. These effects could be reverted by incubating Col6a1 null muscle fibres with cyclosporin A (CsA), an inhibitor of the mitochondrial permeability pore; more interestingly, the treatment of Col6a1 null mice with CoA rescued the muscle phenotype in vivo. These findings demonstrated an unexpected collagen VI/mitochondrial connection as the basis for the UCMD and BM pathogenesis and suggested a strategy for a possible pharmacological treatment of the diseases. This was assessed by demonstrating that muscle biopsies from patients with UCMD showed an abnormal mitochondrial depolarization and that treatment with CsA normalized the mitochondrial phenotype. In this study we report the results of an open pilot trial of four UCMD and one BM patients, representing a range of collagen VI deficiency and having mutations in three of the collagen VI genes. As determined in muscle biopsies prior to treatment, all patients displayed mitochondrial dysfunction and muscle fibres showed an increased frequency of apoptosis. When patients were treated for 1 month with a low daily dose of CsA, primary muscle cell cultures of biopsies obtained at the end of the treatment showed a decreased apoptosis and increased immunohistochemical signs of muscle fibre regeneration. These results confirm that the pathogenic mechanism found in Col6a1 deficient mice also plays a crucial role in hereditary muscle diseases in human, and suggest that targeted treatment of these mitochondrial defects in patients with UCMD and BM may be effective in preventing and/or reverting muscle alterations. It is also important to consider that desensitization of the permeability transition pore by CsA occurs independently of calcineurin inhibition; because a CsA derivative that has no immunosuppressive activity appears to be as effective as the parent molecule, long-term trials should be designed to prevent irreversible muscle damages in young patients affected by collagen VI myopathies, without exposing them to infective risks.",
author = "Maraldi, {Nadir M.} and Patrizia Sabatelli and Marta Columbaro and Alessandra Zamparelli and Manzoli, {Francesco A.} and Paolo Bernardi and Paolo Bonaldo and Luciano Merlini",
year = "2009",
doi = "10.1016/j.advenzreg.2008.12.009",
language = "English",
volume = "49",
pages = "197--211",
journal = "Advances in Enzyme Regulation",
issn = "0065-2571",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Collagen VI myopathies

T2 - From the animal model to the clinical trial

AU - Maraldi, Nadir M.

AU - Sabatelli, Patrizia

AU - Columbaro, Marta

AU - Zamparelli, Alessandra

AU - Manzoli, Francesco A.

AU - Bernardi, Paolo

AU - Bonaldo, Paolo

AU - Merlini, Luciano

PY - 2009

Y1 - 2009

N2 - Collagen VI is an ECM protein which forms a prominent microfibrillar network in the endomysium of skeletal muscle. Mutations in the genes coding for the three chains of collagen VI cause skeletal muscle diseases; the severe wasting Ullrich congenital muscular dystrophy (UCMD) normally present at birth, and the milder Bethlem myopathy (BM). The pathogenesis of both collagen VI myopathies was unknown until 2003. Our group, utilizing Col6a1 deficient mice, discovered a latent mitochondrial dysfunction that caused increased apoptosis in muscle cells. These effects could be reverted by incubating Col6a1 null muscle fibres with cyclosporin A (CsA), an inhibitor of the mitochondrial permeability pore; more interestingly, the treatment of Col6a1 null mice with CoA rescued the muscle phenotype in vivo. These findings demonstrated an unexpected collagen VI/mitochondrial connection as the basis for the UCMD and BM pathogenesis and suggested a strategy for a possible pharmacological treatment of the diseases. This was assessed by demonstrating that muscle biopsies from patients with UCMD showed an abnormal mitochondrial depolarization and that treatment with CsA normalized the mitochondrial phenotype. In this study we report the results of an open pilot trial of four UCMD and one BM patients, representing a range of collagen VI deficiency and having mutations in three of the collagen VI genes. As determined in muscle biopsies prior to treatment, all patients displayed mitochondrial dysfunction and muscle fibres showed an increased frequency of apoptosis. When patients were treated for 1 month with a low daily dose of CsA, primary muscle cell cultures of biopsies obtained at the end of the treatment showed a decreased apoptosis and increased immunohistochemical signs of muscle fibre regeneration. These results confirm that the pathogenic mechanism found in Col6a1 deficient mice also plays a crucial role in hereditary muscle diseases in human, and suggest that targeted treatment of these mitochondrial defects in patients with UCMD and BM may be effective in preventing and/or reverting muscle alterations. It is also important to consider that desensitization of the permeability transition pore by CsA occurs independently of calcineurin inhibition; because a CsA derivative that has no immunosuppressive activity appears to be as effective as the parent molecule, long-term trials should be designed to prevent irreversible muscle damages in young patients affected by collagen VI myopathies, without exposing them to infective risks.

AB - Collagen VI is an ECM protein which forms a prominent microfibrillar network in the endomysium of skeletal muscle. Mutations in the genes coding for the three chains of collagen VI cause skeletal muscle diseases; the severe wasting Ullrich congenital muscular dystrophy (UCMD) normally present at birth, and the milder Bethlem myopathy (BM). The pathogenesis of both collagen VI myopathies was unknown until 2003. Our group, utilizing Col6a1 deficient mice, discovered a latent mitochondrial dysfunction that caused increased apoptosis in muscle cells. These effects could be reverted by incubating Col6a1 null muscle fibres with cyclosporin A (CsA), an inhibitor of the mitochondrial permeability pore; more interestingly, the treatment of Col6a1 null mice with CoA rescued the muscle phenotype in vivo. These findings demonstrated an unexpected collagen VI/mitochondrial connection as the basis for the UCMD and BM pathogenesis and suggested a strategy for a possible pharmacological treatment of the diseases. This was assessed by demonstrating that muscle biopsies from patients with UCMD showed an abnormal mitochondrial depolarization and that treatment with CsA normalized the mitochondrial phenotype. In this study we report the results of an open pilot trial of four UCMD and one BM patients, representing a range of collagen VI deficiency and having mutations in three of the collagen VI genes. As determined in muscle biopsies prior to treatment, all patients displayed mitochondrial dysfunction and muscle fibres showed an increased frequency of apoptosis. When patients were treated for 1 month with a low daily dose of CsA, primary muscle cell cultures of biopsies obtained at the end of the treatment showed a decreased apoptosis and increased immunohistochemical signs of muscle fibre regeneration. These results confirm that the pathogenic mechanism found in Col6a1 deficient mice also plays a crucial role in hereditary muscle diseases in human, and suggest that targeted treatment of these mitochondrial defects in patients with UCMD and BM may be effective in preventing and/or reverting muscle alterations. It is also important to consider that desensitization of the permeability transition pore by CsA occurs independently of calcineurin inhibition; because a CsA derivative that has no immunosuppressive activity appears to be as effective as the parent molecule, long-term trials should be designed to prevent irreversible muscle damages in young patients affected by collagen VI myopathies, without exposing them to infective risks.

UR - http://www.scopus.com/inward/record.url?scp=66449101938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449101938&partnerID=8YFLogxK

U2 - 10.1016/j.advenzreg.2008.12.009

DO - 10.1016/j.advenzreg.2008.12.009

M3 - Article

C2 - 19162063

AN - SCOPUS:66449101938

VL - 49

SP - 197

EP - 211

JO - Advances in Enzyme Regulation

JF - Advances in Enzyme Regulation

SN - 0065-2571

IS - 1

ER -